Retinopathy Of Prematurity - Pipeline Review, H2 2015

Publisher Name :
Date: 26-Aug-2015
No. of pages: 51
Inquire Before Buying

Global Markets Direct's, ‘Retinopathy Of Prematurity - Pipeline Review, H2 2015', provides an overview of the Retinopathy Of Prematurity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinopathy Of Prematurity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinopathy Of Prematurity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Retinopathy Of Prematurity and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Retinopathy Of Prematurity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Retinopathy Of Prematurity pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Retinopathy Of Prematurity - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Retinopathy Of Prematurity Overview 6
Therapeutics Development 7
Pipeline Products for Retinopathy Of Prematurity - Overview 7
Pipeline Products for Retinopathy Of Prematurity - Comparative Analysis 8
Retinopathy Of Prematurity - Therapeutics under Development by Companies 9
Retinopathy Of Prematurity - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Retinopathy Of Prematurity - Products under Development by Companies 13
Retinopathy Of Prematurity - Companies Involved in Therapeutics Development 14
Acucela Inc. 14
Biomar Microbial Technologies 15
EyeGene, Inc. 16
F. Hoffmann-La Roche Ltd. 17
Gene Signal International SA 18
Insmed Incorporated 19
Retinopathy Of Prematurity - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
aganirsen - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
EG-Mirotin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
emixustat hydrochloride - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
IB-09A0133 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
mecasermin rinfabate (recombinant) - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
R-200 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ranibizumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule for Retinopathy of Prematurity - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Retinopathy Of Prematurity - Recent Pipeline Updates 42
Retinopathy Of Prematurity - Product Development Milestones 49
Featured News & Press Releases 49
Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For IPLEX In Retinopathy Of Prematurity In Infants 49
Apr 29, 2008: Acucela Presents Preclinical Data From Retinopathy Study Demonstrating Improvement In Retinal Abnormalities 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables

Number of Products under Development for Retinopathy Of Prematurity, H2 2015 7
Number of Products under Development for Retinopathy Of Prematurity - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Late Stage Development, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Retinopathy Of Prematurity - Pipeline by Acucela Inc., H2 2015 14
Retinopathy Of Prematurity - Pipeline by Biomar Microbial Technologies, H2 2015 15
Retinopathy Of Prematurity - Pipeline by EyeGene, Inc., H2 2015 16
Retinopathy Of Prematurity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 17
Retinopathy Of Prematurity - Pipeline by Gene Signal International SA, H2 2015 18
Retinopathy Of Prematurity - Pipeline by Insmed Incorporated, H2 2015 19
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Stage and Target, H2 2015 22
Number of Products by Stage and Mechanism of Action, H2 2015 24
Number of Products by Stage and Route of Administration, H2 2015 26
Number of Products by Stage and Molecule Type, H2 2015 28
Retinopathy Of Prematurity Therapeutics - Recent Pipeline Updates, H2 2015 42

List of Figures

Number of Products under Development for Retinopathy Of Prematurity, H2 2015 7
Number of Products under Development for Retinopathy Of Prematurity - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Top 10 Targets, H2 2015 21
Number of Products by Stage and Top 10 Targets, H2 2015 21
Number of Products by Top 10 Mechanism of Actions, H2 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 23
Number of Products by Top 10 Routes of Administration, H2 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 25
Number of Products by Top 10 Molecule Types, H2 2015 27
Number of Products by Stage and Top 10 Molecule Types, H2 2015 27
  • Juvenile Macular Degeneration Treatment Market Insights 2019, Global and Chinese Scenario
    Published: 17-Jan-2019        Price: US 3000 Onwards        Pages: 142
    Juvenile Macular Degeneration Treatment Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Juvenile Macular Degeneration Treatment industry with a focus on the Chinese market. The report provides key statistics on the market status of the Juvenile Macular Degeneration Treatment manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides......
  • Uveitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019
    Published: 15-Jan-2019        Price: US 2000 Onwards        Pages: 60
    Introduction DelveInsight's, "Uveitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Uveitis . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country. Global API Manufacturers of Marketed Products for Uveitis Coverage of API manufacturers for Uvei......
  • Blepharitis - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 50
    "Blepharitis - Pipeline Insight, 2019" report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Blepharitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered......
  • Viral Conjunctivitis - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 50
    "Viral Conjunctivitis - Pipeline Insight, 2019" report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Viral Conjunctivitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipelin......
  • Uveal Melanoma - Epidemiology Forecast to 2028
    Published: 15-Jan-2019        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "Uveal Melanoma - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Uveal Melanoma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Uveal Melanoma Epidemiology The epidemiology section covers th......
  • Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 50
    "Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Insight, 2019" report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Juvenile Macular Degeneration (Stargardt Disease) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route o......
  • Wet Macular Degeneration - Epidemiology Forecast to 2028
    Published: 15-Jan-2019        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "Wet Macular Degeneration - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Wet Macular Degeneration epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2028 Wet Macular Degeneration Epidemiology The ......
  • Leber's Hereditary Optic Neuropathy - Pipeline Insight, 2019
    Published: 15-Jan-2019        Price: US 1250 Onwards        Pages: 50
    "Leber's Hereditary Optic Neuropathy - Pipeline Insight, 2019" report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Leber's Hereditary Optic Neuropathy development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecul......
  • Retinal Vein Occlusion - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019
    Published: 15-Jan-2019        Price: US 2000 Onwards        Pages: 60
    Introduction DelveInsight's, "Retinal Vein Occlusion - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019" report provides comprehensive insights about marketed and Phase III products for Retinal Vein Occlusion . The report includes information of marketed products including their product description, patent details, forecasted sales till 2021 & API manufacturer details by country. Global API Manufacturers of Marketed Products for Retinal Vein Occlusion......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs